CX Institutional Acquires 3,300 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

CX Institutional boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,287 shares of the biopharmaceutical company’s stock after purchasing an additional 3,300 shares during the period. CX Institutional’s holdings in Gilead Sciences were worth $5,938,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in GILD. Encompass More Asset Management grew its holdings in shares of Gilead Sciences by 22.1% in the fourth quarter. Encompass More Asset Management now owns 5,884 shares of the biopharmaceutical company’s stock worth $544,000 after purchasing an additional 1,066 shares during the last quarter. Impact Partnership Wealth LLC grew its holdings in Gilead Sciences by 1.5% in the 4th quarter. Impact Partnership Wealth LLC now owns 12,950 shares of the biopharmaceutical company’s stock worth $1,196,000 after acquiring an additional 194 shares during the last quarter. Southland Equity Partners LLC increased its position in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 110 shares during the period. RFG Advisory LLC raised its stake in shares of Gilead Sciences by 4.4% during the fourth quarter. RFG Advisory LLC now owns 13,910 shares of the biopharmaceutical company’s stock valued at $1,285,000 after acquiring an additional 581 shares during the last quarter. Finally, Oliver Luxxe Assets LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $4,463,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $92.91 on Friday. The company has a 50 day moving average of $91.63 and a 200 day moving average of $84.63. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The firm has a market cap of $115.79 billion, a P/E ratio of 1,032.52, a PEG ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the company posted $2.29 earnings per share. The company’s quarterly revenue was up 7.0% on a year-over-year basis. As a group, research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.32%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last ninety days. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on GILD. UBS Group boosted their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Piper Sandler boosted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.